What is it? Why is it important?

A generic medicinal product is an additional brand of an already existing Medicinal Product (i.e. the original preparation).  

 

An “original preparation” is the first Medical Product with a specific active substance (i.e. the chemistry that makes the drug work) that has been authorised by regulatory authorities (i.e. including all authorised dosage forms).

 

A generic medicinal product:

  • Is essentially the same as an original preparation as it contains the same active ingredient (e.g. bioequivalent)
  • Is interchangeable with the original preparation due to its identical active substances, administration route (e.g. tablet, injection, infusion) and dosage form (e.g. x mg / day, x ml / per body weight)
  • Complies with the same safety and quality criteria as the original preparation.

 

The acceptance criteria of the generic drug must be no less than 80% or no more than 125% of the original product, and must be authorised by regulatory authorities (e.g. Swissmedic)

More

Reference preparation:

  • Is a biological Medicinal Product
  • Is used in the authorisation documentation for a biosimilar product as a reference for the comparability of its pharmaceutical quality, efficacy and safety

Biosimilar product:

  • Biological medicinal product
  • Sufficiently similar to a reference preparation authorised by the Swissmedic
  • Refers to its documentation

What do I need to do?

Note: The “Drug & Device” section addresses Medicinal Products and Medical Devices. “In Vitro Medical Devices” are not discussed In the Easy-GCS.

Where can I get help?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

Swiss Law

TPA – see in particular article

  • Art. 4 Definition generic medicinal products
Basic ↦ Drug or Device ↦ Therapeutic Products ↦ Generic Products
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Basic ↦ Drug or Device ↦ Therapeutic Products ↦ Generic Products

Please note: the Easy-GCS tool is currently under construction.